Skip to main content
PAYS
NASDAQ Trade & Services

Paysign Reports Record Q1 2026 Results with 51% Revenue Growth, Doubles Net Income; Authorizes New $5M Share Buyback

Analysis by Arik Shkolnikov
Sentiment info
Positive
Importance info
9
Price
$6.305
Mkt Cap
$366.983M
52W Low
$2.76
52W High
$8.88
Market data snapshot near publication time

summarizeSummary

Paysign, Inc. reported outstanding Q1 2026 financial results with 51% revenue growth and a 110% increase in net income, alongside a significant positive swing in operating cash flow. The company also authorized a new $5 million share repurchase program.


check_boxKey Events

  • Record Q1 2026 Financial Performance

    Total revenues increased by $9.44 million (50.8%) to $28.04 million for Q1 2026, compared to $18.60 million in Q1 2025. Net income more than doubled, rising by $2.85 million (110.3%) to $5.44 million from $2.59 million in the prior year period. Basic EPS increased to $0.10 from $0.05, and diluted EPS increased to $0.09 from $0.05.

  • Strong Operating Cash Flow Turnaround

    Net cash provided by operating activities was $18.79 million for Q1 2026, a significant improvement from net cash used in operating activities of $(6.03) million in Q1 2025. This positive shift reflects strong operational performance and effective working capital management.

  • Adjusted EBITDA More Than Doubles

    Adjusted EBITDA increased by $5.63 million (113.4%) to $10.59 million for Q1 2026, up from $4.96 million in Q1 2025, indicating enhanced profitability and operational efficiency.

  • New $5 Million Share Repurchase Program Authorized

    The Board of Directors authorized a new stock repurchase program on May 8, 2026, to repurchase up to $5 million of common stock over a 36-month period. This follows the expiration of a previous $5 million program on March 20, 2026, under which $1.99 million of shares were repurchased.


auto_awesomeAnalysis

Paysign, Inc. delivered exceptionally strong first-quarter 2026 financial results, demonstrating significant growth across key metrics. Revenue surged by 51% year-over-year, driven by expansion in both plasma and pharma patient affordability programs. Net income more than doubled, and the company achieved a substantial turnaround in operating cash flow, moving from a negative outflow in the prior year to a strong positive inflow. This robust performance indicates successful execution of growth strategies and improved operational efficiency. Additionally, the Board authorized a new $5 million share repurchase program, signaling confidence in the company's valuation and future prospects. This filing provides the full financial details following a preliminary announcement, confirming a very positive outlook.

At the time of this filing, PAYS was trading at $6.31 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $367M. The 52-week trading range was $2.76 to $8.88. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed PAYS - Latest Insights

PAYS
May 13, 2026, 7:36 AM EDT
Filing Type: 10-Q
Importance Score:
9
PAYS
May 12, 2026, 4:20 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
PAYS
May 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
PAYS
Mar 26, 2026, 7:33 AM EDT
Filing Type: DEF 14A
Importance Score:
7
PAYS
Mar 25, 2026, 8:05 AM EDT
Filing Type: 10-K
Importance Score:
9
PAYS
Mar 24, 2026, 4:11 PM EDT
Source: Reuters
Importance Score:
8
PAYS
Mar 24, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8